How I Serve
I don’t endorse. Only disseminate.
The 411: Investment Opportunity - Preventing A Second Stroke is Critical
Preventing A Stroke at Home:
Each year nearly 800,000 people in the U.S. experience a new or recurrent stroke, and stroke is the fifth leading cause of death in the U.S. Up to 80 percent of strokes can be prevented, and our mission is to give surviving stroke patients, diabetics, and others a home testing device that can give an early warning sign and help prevent stroke at home.
We are developing an easy-to-use home test to monitor the risk of stroke. The device is based on our patented and proven technology, based on biomarker detection that is both accurate, low cost and simple to use.
Stroke Screening Home Test:
Take control of your health from the comfort of your home
Our goal is to develop and bring to the market an end-to-end screening platform that will enable users to monitor their stroke risk on a daily or weekly basis. The test procedure is simple and requires only a drop of blood. The drop is put onto the disposable, one-time-use test strip. This strip is then inserted into the handheld reader. The reader will be bluetooth-enabled and connected to a smartphone mobile application that will gather and process the information. The application will provide users with a warning and alert if their biomarkers reach high-risk levels and instruct them to visit a physician.
Strokes can be prevented:
Up to 80 percent of strokes can be prevented. Risk of stroke
can be reduced by lowering blood pressure,losing weight,
exercising,treating diabetes, treating atrial fibrillation,
quitting drinking, and quitting
smoking. These are all effective ways to reduce the risk of
stroke, but today there is no way to
assess and monitor the risk of stroke at home.
We aim to do just that. Our solution is to monitor the risk of
stroke using a simple-to-use blood test, similar to the
glucose test used by diabetic patients. This was not available
up to now because there was no affordable way to measure
disease markers at home. Our technology enables that.
How do we do it?
We measure a heart failure blood marker that, when elevated,
indicates a high risk of stroke. A weakened heart cannot pump
blood efficiently, and that can lead to the formation of blood
clots that can cause a stroke. With continuous monitoring -
at least once a week - we will be able to provide an early
warning sign and recommend a visit to a physician who will
provide the final diagnostics and treatment. Our stroke
screening test is NOT intended to be a substitute for
professional medical advice, diagnosis, or treatment. Always
talk to your doctor or other healthcare provider about any
questions you have about medical conditions.
How big is the opportunity?
It's huge. Our target consumers are stroke survivors and
diabetics. In the U.S. alone there are 6.5 million stroke
survivors (data from National Stroke Association) and over
10 million diabetics over 40-years old (data from CDC).
Considering only the basic subscription model, this amounts
to a market opportunity of $9.9 billion per year.
Who benefits the most?
Stroke survivors and diabetic patients are at the highest risk
of stroke and are therefore the main groups that we want to
reach. Our stroke screening test still requires a blood prick,
and that is often a barrier for a number of healthy people.
However, this is not the case with people who have
experienced the terrifying consequences of stroke and also
with diabetic patients who have to do a daily blood pricks to
monitor their glucose levels.
Founder and CEO
Luka comes from Slovenia and holds a PhD in Medical
Microbiology. Before starting the company he was doing
research and clinical laboratory diagnostics of hemorrhagic
fevers, biothreats and other infectious diseases. He spent a
lot of time in the field, helping doctors and nurses in
low-income countries to set up and improve their diagnostic
preparedness. During his work, he saw firsthand the
drawbacks of the existing medical diagnostics system that is
mostly centralized, capital-intensive, with many people
not enjoying adequate access to it. That was the motivation
to join Prof. Robert's laboratory in Singapore where he took
over the fundraising and startup activities of the technology.
He continued as CEO of Biosensorix and helped secure early
funding and directed the research and development activities.
He is a passionate entrepreneur with deep knowledge of
diagnostics, user expectations, and basic science.
Founder and Chief Scientist
Prof. Dr. Robert S. Marks is the co-inventor of the
technological platform and is a renowned expert
and key opinion leader in the field of biosensors. He is a
Full Professor at the Ben-Gurion University of the Negev,
Israel, at the Department of Biotechnology Engineering,
The National Institute for Biotechnology in the
Negev and the Ilse Kats Centre for Nanotechnology. He is
presently a Visiting Scientist in the NTU-MSE, and was a
program coordinator for the NRF CREATE program
“Nanomaterials for Water and Energy Management”.
Robert has previously co-founded Biosensing Technologies
Ltd, Biopixel Ltd and Polyrizon Ltd. He will be assisting with
advising the development of the next generation
prototype and establishing the business collaboration with
potential partners. Prof. Marks has extensive experience in
development of biosensors. He is the Editor-in-Chief of a
2007 2-volume Wiley Handbook in Biosensors and Biochips
and a 2014 Viral Diagnostics book for virus detection.
He is the author of 150+ papers (H-index 27), and numerous
chapters. He has 4 issued patents as well as a dozen filed.
No comments:
Post a Comment